Exact Sciences Corporation

Problem solving in innovative ways is the story, and the science behind Exact Sciences. Starting with the early development and through the commercialization of our noninvasive colorectal cancer screening test, Cologuard, we solved problems and employed innovative strategies every step of the way.The multitarget stool DNA test (Cologuard) was developed using the principles of biology, chemistry and molecular biology. As a result, it is a powerful combination of technologies packaged into one convenient and highly effective precancer and cancer screening test.In creating a stool DNA-based test, we sought to incorporate the most discriminating and informative biomarkers to ensure the highest possible sensitivity in detecting colorectal cancer. 

Bank Name Exact Sciences Corporation
Stock Exchange NASDAQ
Symbol EXAS
Sector Healthcare
Industry Biotechnology: Commercial Physical
Country United States
World Region America
CEO Mr. Kevin T. Conroy
Employees 1268
Website www.exactsciences.com
Registered Year 1995